Plus Therapeutics, Inc.
PSTV
$0.2025
-$0.1061-34.38%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.06M | 1.41M | 1.46M | 1.28M | 1.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06M | 1.41M | 1.46M | 1.28M | 1.68M |
| Cost of Revenue | 1.76M | 2.19M | 2.86M | 2.77M | 2.76M |
| Gross Profit | -697.00K | -774.00K | -1.40M | -1.49M | -1.09M |
| SG&A Expenses | 2.84M | 3.13M | 2.40M | 2.20M | 2.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.60M | 5.31M | 5.26M | 4.98M | 4.98M |
| Operating Income | -3.54M | -3.90M | -3.80M | -3.70M | -3.30M |
| Income Before Tax | -17.40M | -3.90M | -2.87M | -2.94M | -3.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.40M | -3.90M | -2.87M | -2.94M | -3.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.40M | -3.90M | -2.87M | -2.94M | -3.26M |
| EBIT | -3.54M | -3.90M | -3.80M | -3.70M | -3.30M |
| EBITDA | -3.39M | -3.70M | -3.60M | -3.53M | -3.14M |
| EPS Basic | -1.19 | -0.50 | -0.37 | -0.45 | -0.75 |
| Normalized Basic EPS | -0.75 | -0.31 | -0.23 | -0.28 | -0.47 |
| EPS Diluted | -1.19 | -0.50 | -0.37 | -0.71 | -0.75 |
| Normalized Diluted EPS | -0.75 | -0.31 | -0.23 | -0.17 | -0.47 |
| Average Basic Shares Outstanding | 14.57M | 7.86M | 7.86M | 6.50M | 4.32M |
| Average Diluted Shares Outstanding | 14.57M | 7.86M | 7.86M | 10.74M | 4.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |